» Articles » PMID: 38782781

Development of a Nine-variant Reference Material Panel to Standardize Cell-free DNA Detection

Overview
Specialty Chemistry
Date 2024 May 23
PMID 38782781
Authors
Affiliations
Soon will be listed here.
Abstract

Detection of specific gene mutations in cell-free DNA (cfDNA) serves as a valuable cancer biomarker and is increasingly being explored as an appealing alternative to tissue-based methods. However, the lack of available reference materials poses challenges in accurately evaluating the performance of different assays. In this study, we present the development of a comprehensive reference material panel for cfDNA detection, encompassing nine hotspot mutations in KRAS/BRAF/EGFR/PIK3CA at three variant allele frequencies (VAFs), ranging from 0.33 to 23.9%. To mimic cfDNA, these reference materials were generated by enzymatically digesting cell-line DNA into approximately 154-bp to 173-bp fragments using a laboratory-developed reaction system. The VAFs for each variation were precisely determined through validated digital PCR assays with high accuracy. Furthermore, the reliability and applicability of this panel were confirmed through two independent NGS assays, yielding concordant results. Collectively, our findings suggest that this novel reference material panel holds great potential for validation, evaluation, and quality control processes associated with liquid biopsy assays.

References
1.
Zulato E, Del Bianco P, Nardo G, Attili I, Pavan A, Boscolo Bragadin A . Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors. Br J Cancer. 2022; 127(11):2034-2042. PMC: 9681746. DOI: 10.1038/s41416-022-01978-1. View

2.
Song P, Wu L, Yan Y, Zhang J, Chu T, Kwong L . Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nat Biomed Eng. 2022; 6(3):232-245. PMC: 9336539. DOI: 10.1038/s41551-021-00837-3. View

3.
Zhu Z, Hu E, Shen H, Tan J, Zeng S . The functional and clinical roles of liquid biopsy in patient-derived models. J Hematol Oncol. 2023; 16(1):36. PMC: 10082989. DOI: 10.1186/s13045-023-01433-5. View

4.
Peng W, Liu Y, Sha H, Wen S, Fang Y, Zhou G . Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer. BMC Pulm Med. 2023; 23(1):348. PMC: 10503004. DOI: 10.1186/s12890-023-02586-2. View

5.
Pessoa L, Heringer M, Ferrer V . ctDNA as a cancer biomarker: A broad overview. Crit Rev Oncol Hematol. 2020; 155:103109. DOI: 10.1016/j.critrevonc.2020.103109. View